James R. Kasinger, General Counsel of Crispr Therapeutics CRSP, has filed 0 purchases and 15 sales on the open market. Over the past 12 months that comes to a net sale of $1.3M. The latest trade was on 09/22.

James R. Kasinger

General Counsel and Secretary

Company

Crispr Therapeutics CRSP

First filing

23/02/22

Trades

68 trades

Buys / sales

0 / 15

12-month net buying

−$1.3M

Last trade

09/22

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Crispr TherapeuticsCRSP	Open-market sale10b5-1 plan	09/22	09/24	10,400 sh	$60.24	$626,459.6	−9.9%
Crispr TherapeuticsCRSP	Open-market sale	03/23	03/24	3,182 sh	$46.78	$148,853.96	−3.3%
Crispr TherapeuticsCRSP	Open-market sale	03/16	03/17	3,450 sh	$48.26	$166,497	−3.6%
Crispr TherapeuticsCRSP	Open-market sale	03/11	03/12	2,800 sh	$52.80	$147,840	−3.1%
Crispr TherapeuticsCRSP	Open-market sale	02/19	02/20	2,112 sh	$52.58	$111,048.96	−2.4%
Crispr TherapeuticsCRSP	Open-market sale	25/10/14	25/10/15	1,076 sh	$66.60	$71,661.6	−1.3%
Crispr TherapeuticsCRSP	Open-market sale	25/03/21	25/03/24	3,185 sh	$41.23	$131,317.55	−3.8%
Crispr TherapeuticsCRSP	Open-market sale	25/03/11–25/03/12	25/03/12	3,966 sh2 trades	$42.67avg.	$169,242.12	−4.8%
Crispr TherapeuticsCRSP	Open-market sale	25/02/18–25/02/19	25/02/19	11,542 sh2 trades	$53.67avg.	$619,492.35	−13.4%
Crispr TherapeuticsCRSP	Open-market sale	24/10/14	24/10/15	1,089 sh	$46.28	$50,398.92	−1.7%
Crispr TherapeuticsCRSP	Open-market sale	24/03/11–24/03/12	24/03/12	3,947 sh2 trades	$77.15avg.	$304,514.5	−6.1%
Crispr TherapeuticsCRSP	Open-market sale	24/02/20	24/02/21	1,913 sh	$79.67	$152,408.71	−3.2%